Navigation Links
NuVasive to Present at Canaccord Adams' Small-Cap Orthopedics Conference
Date:2/27/2008

SAN DIEGO, Feb. 27 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Executive Vice President and Chief Financial Officer, is scheduled to present at the Canaccord Adams' Small-Cap Orthopedics Conference at The Mission Bay Conference Center at UCSF, in San Francisco, CA on Tuesday, March 4, 2008 at 8:10 a.m. PT.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact: Investors:

Kevin C. O'Boyle Nick Laudico/Zack Kubow

EVP & Chief Financial Officer The Ruth Group

NuVasive, Inc. 646-536-7030/7020

858-909-1800 nlaudico@theruthgroup.com

investorrelations@nuvasive.com zkubow@theruthgroup.com

Media:

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
2. NuVasive to Host Investor Reception on September 11, 2007
3. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
4. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
5. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
7. National Stem Cell Holding, Inc. to Present Keynote Address at The Stem Cell Partnering Series Inaugural Meeting in San Diego
8. NeoStem to Present at Third Annual Stem Cell Summit in New York City
9. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
10. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
11. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... During a two day program for start-up ... CereScan’s CEO, John Kelley, joined other Denver business leaders in providing business basics ... Denver area business community, shared his top fundamental learnings in building an effective, ...
(Date:4/28/2016)... 28, 2016 Q BioMed ... Company,s CEO  was featured in an article he ... VCs Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... is an essential business journal for life ... biotechs to Big Pharmas. Their content is designed ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and data ... to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” , ... of end users facing some of the most complex data challenges in the industry,” ...
(Date:4/27/2016)... Md. and RESEARCH TRIANGLE PARK, ... Corporation (NASDAQ: UTHR ) announced today that ... Officer, of United Therapeutics will provide an overview and ... 41 st Annual Health Care Conference. ... 2016, at 10:00 a.m. Eastern Time, and can be ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):